OA09.03 Randomized, Open-Label, Phase III Study of SAF-189s Versus Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Ao Xiong(China Construction Eighth Engineering Division (China)), Chun Zhou(Nanfang Hospital), Jingzhou Hu(Shanghai Stomatological Hospital), Jiayue Cui(Jilin University), Weitao Yao(Sichuan Cancer Hospital), Haitao Niu(Qingdao University), Jianying Zhou(First Affiliated Hospital Zhejiang University), Xinxin Xiang(Memorial University of Newfoundland), Dandan Huang(Sun Yat-sen University), Ling Xu(Xinyang Central Hospital), Junwei Fang(Peking University), Hua Wu(Henan Cancer Hospital), Ming Li(Zhengzhou University), Hongliang Liu(Fosun Pharma (China)), Yuping Li(Guangdong Province Women and Children Hospital), Xiaonan Wang(Central South University), Li Liu(Illumina (United States)), Zhaohui Zhang(Peking University), Z. Wu(Fosun Pharma (China)), Xiaowei Dong(Unimed Medical Institute), Hao Qin(First Affiliated Hospital of Xi'an Jiaotong University), Liang Yu(Ocean University of China), Yihong Zhang(Xihua University), Yingying Fan(Xidian University), Ruanqi Chen(Liuzhou General Hospital), Songwei Guo(The Affiliated Yongchuan Hospital of Chongqing Medical University), Ning Yang(First Affiliated Hospital of Hebei Medical University), Peng Pan(Guangzhou Medical University), M. Wang(Xiamen University), Wen Su(Guangdong Medical College)
Cited by 2
Related Papers
Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19)
|Clinical Infectious Diseases|2020|556